Corbus Pharmaceuticals Holdings, Inc. (CRBP) Earnings Call Transcripts

Corbus Pharmaceuticals Holdings, Inc.'s Latest Earnings Call - June 1, 2026

In the Q2 2026 earnings call for Corbus Pharmaceuticals, management discussed the upcoming registrational study for CRB-701, an antibody-drug conjugate targeting Nectin-4 in oropharyngeal cancer. The company anticipates a significant patient population due to rising incidences of HPV-positive oropharyngeal cancer, with estimates of 7,500 to 10,000 recurrent patients in the U.S. alone. Management maintained guidance for the upcoming trial, emphasizing the unmet need in this segment and the potential for CRB-701 to outperform existing therapies, particularly in the second-line setting. Revenue and earnings figures were not disclosed, but the focus on trial enrollment and patient demographics could influence stock movement in the near term.

Reported metrics

Guidance from management

Management maintained guidance for the upcoming registrational study of CRB-701, emphasizing the significant unmet need in the oropharyngeal cancer segment and the potential for the drug to outperform existing therapies.

What management said

Like ESMO, we're going to keep it very conversational and not particularly scripted, and we absolutely welcome any questions you have here. I'd say, let's start with the member one question. I've gotten and my team has gotten since the data came out last Tuesday, which is how many patients are we talking about? And so if we can sort of deconstruct that question, let's start with, before we even talk about the patient...

Dr. Perz, I want to follow up on that with you and the rest of the panel because I think there is an interesting dynamic, right, between even geographically, if we think about different places in the world, we have "the West" where as you mentioned, Dr. Perez, those of you who've noticed the youth are no longer smoking or particularly drinking and then we have places such as Asia or South America, where it's still ve...

What analysts pressed on

Analysts expressed concerns about the effectiveness of current second-line treatments and the potential challenges in managing ocular toxicity associated with CRB-701. There were also questions regarding the trial's ability to enroll a representative HPV-positive patient population.

Main topics on the call

• Patient Population Insights — Management highlighted that the oropharyngeal cancer patient population is largely HPV-positive, with estimates suggesting that 15% to 25% of these patients will develop recurrence. Dr. Hanna noted, "the vast majority of...
• Unmet Need in Second-Line Treatment — The panel discussed the lack of effective second-line therapies for HPV-positive patients, with Dr. Batista stating, "there's no good second line... there's none, right?" This underscores the potential for CRB-701 to fil...
• Anticipated Response Rates — Management indicated that a response rate of 30% to 40% would be considered favorable for CRB-701 in the registrational trial. Dr. Rosenberg mentioned, "if we're looking at response rates in the arena of 30%, 40%, that's...
• Challenges with Ocular Toxicity — The panel addressed concerns regarding ocular toxicity associated with CRB-701, noting that while it is a manageable side effect, it requires monitoring. Dr. Hanna stated, "ocular toxicity... sounds scary, right, its vis...

Read the full Corbus Pharmaceuticals Holdings, Inc. transcript (June 1, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 15 Corbus Pharmaceuticals Holdings, Inc. earnings call transcripts on record, spanning March 12, 2020 to September 14, 2026. Based on this history, Corbus Pharmaceuticals Holdings, Inc. reports semi-annually. The most recent call on file is dated September 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CRBP

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

15

First call

March 12, 2020

Most recent

September 14, 2026

Reporting cadence

semi-annually